Lyme disease vaccines

Vaccines: Sixth Edition

Volumn , Issue , 2012, Pages 1122-1132

  Steere, Allen C ^a   Livey, Ian ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BAXTER BIOSCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880701504     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0090-5.00055-0     Document Type: Chapter

References (184)

1. Steere A.C., Sikand V.K., Meurice F., et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface protein lipoprotein A with adjuvant. N Engl J Med 1998, 339:209-215.
2. Fikrig E., Barthold S.W., Kantor F.S., et al. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 1990, 250:553-556.
3. Golde W.T., Piesman J., Dolan M.C., et al. Reactivity with a specific epitope of outer surface protein A predicts for protection from infection with the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun 1997, 65:882-889.
4. Sigal L.H., Zahradnik J.M., Lavin P., et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium [see comments]. N Engl J Med 1998, 339:216-222. (See erratum in N Engl J Med 339:571, 1998.).
5. Steere A.C., Drouin E.E., Glickstein L.J. Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis. Clin Infect Dis 2011, 52:S259-S265.
6. Plotkin S.A. Correcting a public health fiasco: the need for a new vaccine against Lyme disease. Clin Infect Dis 2011, 52:S271-S275.
7. Livey I., O'Rourke M., Traweger A., et al. A new approach to a Lyme disease vaccine. Clin Infect Dis 2011, 52:S266-S270.
8. Scheckelhoff M.R., Telford S.R., Hu L.T. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Vaccine 2006, 24:1949-1957.
9. Narasimhan S., DePonte K., Marcantonio N., et al. Immunity against Ixodes scapularis salivary proteins expressed during the first 24 hours of attachment thwarts tick feeding and impairs Borrelia transmission. PloS One 2007, 2:e451.
10. Shen A.K., Mead P.S., Beard C.B. The Lyme disease vaccine: a public health perspective. Clin Infect Dis 2011, 52:S247-S252.
11. Steere A.C., Malawista S.E., Snydman D.R., et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three Connecticut communities. Arthritis Rheum 1977, 20:7.
12. Steere A.C., Malawista S.E., Hardin J.A., et al. Erythema chronicum migrans and Lyme arthritis: the enlarging clinical spectrum. Ann Intern Med 1977, 86:685.
13. Steere A.C., Broderick T.F., Malawista S.E. Erythema chronicum migrans and Lyme arthritis: epidemiologic evidence for a tick vector. Am J Epidemiol 1978, 108:312.
14. Afzelius A. Erythema chronicum migrans. Acta Derm Venereol (Stockh) 1921, 2:120.
15. Bannwarth A. Zur Klinik und Pathogenese der "chronischen lymphocytaren Meningitis". Arch Psychiatr Nervenkrankh 1944, 117:161.
16. Herxheimer K., Hartmann K. Ueber Acrodermatitis chronica atrophicans. Arch Dermatol Syph 1902, 61:57-76. 255-300.
17. Burgdorfer W., Barbour A.G., Hayes S.F., et al. Lyme disease: a tick-borne spirochetosis?. Science 1982, 216:1317.
18. Steere A.C., Grodzicki R.L., Kornblatt A.N., et al. The spirochetal etiology of Lyme disease. N Engl J Med 1983, 308:733.
19. Benach J.L., Bosler E.M., Hanrahan J.P., et al. Spirochetes isolated from the blood of two patients with Lyme disease. N Engl J Med 1983, 308:740.
20. Ackermann R., Kabatzki J., Boisten H.P., et al. Spirochaten: Atiologie der Erythema-chronicum-migrans-Krankheit. Dtsch Med Wochenschr 1984, 109:92.
21. Preac-Mursic V., Wilske B., Schierz G., et al. Repeated isolation of spirochetes from the cerebrospinal fluid of a patient with meningoradiculitis Bannwarth. Eur J Clin Microbiol 1984, 3:564.
22. Asbrink E., Hovmark A. Successful cultivation of spirochetes from skin lesions of patients with erythema chronica migrans afzelius and acrodermatitis chronica atrophicans. Acta Pathol Microbiol Immunol Scand 1985, 93:161.
23. Baranton G., Assous M., Postic D. Three bacterial species associated with Lyme borreliosis: clinical and diagnostic implications. Bull Acad Natl Med 1992, 176:1075.
24. Bacon R.M., Kugeler K.J., Mead P.S. Surveillance for Lyme disease: United States, 1992-2006. MMWR Surveill Summ 2008, 57:1-9.
25. Steere A.C. Lyme disease. N Engl J Med 1989, 321:586.
26. Steere A.C., Sikand V.K. The presenting manifestations of Lyme disease and outcomes of treatment. N Engl J Med 2003, 348:2472.
27. Nadelman R.B., Nowakowski J., Forseter G., et al. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am J Med 1996, 100:502.
28. Smith R.P., Schoen R.T., Rahn D.W., et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med 2002, 136:421.
29. Reik L., Steere A.C., Bartenhagen N.H., et al. Neurologic abnormalities of Lyme disease. Medicine (Baltimore) 1979, 58:281.
30. Pachner A.R., Steere A.C. The triad of neurologic manifestations of Lyme disease: meningitis, cranial neuritis, and radiculoneuritis. Neurology 1985, 35:47.
31. Steere A.C., Batsford W.P., Weinberg M., et al. Lyme carditis: cardiac abnormalities of Lyme disease. Ann Intern Med 1980, 93:8.
32. Marcus L.C., Steere A.C., Duray P.H., et al. Fatal pancarditis in a patient with coexistent Lyme disease and babesiosis: demonstration of spirochetes in the myocardium. Ann Intern Med 1985, 103:374.
33. Steere A.C., Schoen R.T., Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987, 107:725.
34. Steere A.C., Duray P.H., Butcher E.C. Spirochetal antigens and lymphoid cell surface markers in Lyme synovitis: comparison with rheumatoid synovium and tonsillar lymphoid tissue. Arthritis Rheum 1988, 31:487.
35. Akin E., Aversa J., Steere A.C. Expression of adhesion molecules in synovia in patients with treatment-resistant Lyme arthritis. Infect Immun 2001, 69:1774.
36. Logigian E.L., Kaplan R.F., Steere A.C. Chronic neurologic manifestations of Lyme disease. N Engl J Med 1990, 323:1438.
37. Halperin J.J., Volkman D.J., Wu P. Central nervous system abnormalities in Lyme neuroborreliosis. Neurology 1991, 41:1571.
38. Halperin J.J., Little B.W., Coyle P.K., et al. Lyme disease: cause of a treatable peripheral neuropathy. Neurology 1987, 37:1700.
39. Logigian E.L., Steere A.C. Clinical and electrophysiologic findings in chronic neuropathy of Lyme disease. Neurology 1992, 42:303.
40. Steere A.C., Berardi V.P., Weeks K.E., et al. Evaluation of the intrathecal antibody response to Borrelia burgdorferi as a diagnostic test for Lyme neuroborreliosis. J Infect Dis 1990, 161:1203.
41. Steere A.C. Lyme disease. N Engl J Med 2001, 345:115-125.
42. Feder H.M., Johnson B.J.B., O'Connell S., et al. A critical appraisal of chronic Lyme disease. N Engl J Med 2007, 357:1422.
43. Barbour A.G., Hayes S.F. Biology of Borrelia species. Microbiol Rev 1986, 50:381.
44. Fraser C.M., Casjens S., Huang W.M., et al. Genomic sequence of a Lyme disease spirochete, Borrelia burgdorferi. Nature 1997, 390:580.
45. Casjens S., Palmer N., Van Vugt R., et al. A bacterial genome in flux: the twelve linear and nine circular extrachromosomal DNAs in an infectious isolate of the Lyme disease spirochete Borrelia burgdorferi. Mol Microbiol 2000, 35:490.
46. Zhang J.-R., Norris S.J. Genetic variation of the Borrelia burgdorferi gene VlsE involves cassettes-specific, segmental gene conversation. Infect Immun 1998, 66:3698-3704.
47. de Silva A.M., Fikrig E. Arthropod- and host-specific gene expression by Borrelia burgdorferi. J Clin Invest 1997, 100(suppl):S3.
48. Montgomery R.R., Malawista S.E., Feen K.J.M., et al. Direct demonstration of antigenic substitution of Borrelia burgdorferi ex vivo: exploration of the paradox of the early immune response to outer surface proteins A and C in Lyme disease. J Exp Med 1996, 183:261.
49. Ramamoorthi N., Narasimhan S., Pal U., et al. The Lyme disease agent exploits a tick protein to infect the mammalian host. Nature 2005, 436:573.
50. Kraiczy P., Hellwage J., Sherka C., et al. Complement-resistance of Borrelia burgdorferi correlates with expression of BbCrasp-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins. J Biol Chem 2004, 279:2421.
51. Strle K., Jones K.L., Drouin E.E., et al. Borrelia burgdorferi RST1 (OspC type A) genotype causes greater inflammation and more severe disease. Am J Pathol 2011, 178:2726-2739.
52. Wormser G.P., Brisson D., Liveris D., et al. Borrelia burgdorferi genotype predicts capacity for hematogenous dissemination during early Lyme disease. J Infect Dis 2008, 198:1358.
53. Seinost G., Dykhuizen D.E., Dattwyler R.J., et al. Four clones of Borrelia burgdorferi sensu stricto cause invasive infection in humans. Infect Immun 1999, 67:3518.
54. Coleman J.L., Gebbia J.A., Pieman J., et al. Plasminogen is required for efficient dissemination of B. burgdorferi in ticks and for enhancement of spirochetemia in mice. Cell 1997, 89:1111.
55. Coburn J., Chege W., Magoun L., et al. Characterization of a candidate Borrelia burgdorferi β3-chain integrin identified using a phage display library. Mol Microbiol 1999, 34:926-940.
56. Leong J.M., Robbins D., Rosenfeld L., et al. Structural requirements for glycosaminoglycan recognition by the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun 1998, 66:6045.
57. Probert W.S., Johnson B.J.B. Identification of a 47kDa fibronectin-binding protein expressed by Borrelia burgdorferi isolate B32. Mol Microbiol 1998, 30:1003.
58. Guo B.P., Brown E.L., Dorward D.W., et al. Decorin-binding adhesins from Borrelia burgdorferi. Mol Microbiol 1998, 30:711.
59. Steere A.C., Coburn J., Glickstein L. The emergence of Lyme disease. J Clin Invest 2004, 113:1093.
60. McKisic M.D., Barthold S.W. T-cell-independent responses to Borrelia burgdorferi are critical for protective immunity and resolution of Lyme disease. Infect Immun 2000, 68:5190.
61. Rousselle J.C., Callister S.M., Schell R.F., et al. Borreliacidal antibody production against outer surface protein C of Borrelia burgdorferi. J Infect Dis 1998, 178:733.
62. Fikrig E., Barthold S.W., Sun W., et al. Borrelia burgdorferi P35 and P37 proteins, expressed in, elicit protective immunity. Immunity 1997, 6:531.
63. Keane-Myers A., Nickell S.P. T cell subset-dependent modulation of immunity to Borrelia burgdorferi in mice. J Immunol 1995, 154:1770.
64. Ben-Menachem G.J., Kubler-Kielb J., Coxon B., et al. A newly discovered cholesteryl galactoside from Borrelia burgdorferi. Proc Natl Acad Sci U S A 2003, 100:7913.
65. Jones K.L., Seward R.J., Ben-Menachem G., et al. Strong IgG antibody responses to Borrelia burgdorferi glycolipids in patients with Lyme arthritis, a late disease manifestation. Clin Immunol 2009, 132:93.
66. Duray P.H. The surgical pathology of human Lyme disease: an enlarging picture. Am J Surg Pathol 1987, 11:47.
67. Berger B.W., Johnson R.C., Kodner C., et al. Cultivation of Borrelia burgdorferi from erythema migrans lesions and perilesional skin. J Clin Microbiol 1992, 30:359.
68. Wormser G.P., Bittker S., Cooper D., et al. Yield of large-volume blood cultures in patients with early Lyme disease. J Infect Dis 2001, 184:1070.
69. Coyle P.K., Goodman J.L., Krupp L.B., et al. Lyme disease. Continuum: Lifelong Learning in Neurology 5(4):pt A 1999, Lippincott Williams & Wilkins, Philadelphia, PA.
70. Nocton J.J., Dressler F., Rutledge B.J., et al. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid in Lyme arthritis. N Engl J Med 1994, 330:229.
71. Bradley J.F., Johnson R.C., Goodman J.L. The persistence of spirochetal nucleic acids in active Lyme arthritis. Ann Intern Med 1994, 120:487.
72. Li X., McHugh G., Damle N., et al. Burden and viability of Borrelia burgdorferi in skin or joints of patients with erythema migrans or Lyme arthritis. Arthritis Rheum 2011, 63:2238-2247.
73. Nocton J.J., Bloom B.J., Rutledge B.J., et al. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in patients with Lyme neuroborreliosis. J Infect Dis 1996, 174:623.
74. Wharton M., Chorba T.L., Vogt R.L., et al. Case definitions for public health surveillance. MMWR Recomm Rep 1990, 39(RR-13):1-43.
75. Centers for Disease Control, Prevention Recommendations for test performance and interpretation from the Second International Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995, 44:590-591.
76. Robertson J., Guy E., Andrews N., et al. A European multicenter study of immunoblotting in serodiagnosis of Lyme borreliosis. J Clin Microbiol 2000, 38:2097.
77. Steere A.C., McHugh G., Damle N., et al. Prospective study of serologic tests for Lyme disease. Clin Infect Dis 2008, 47:188.
78. Bacon R.M., Biggerstaff B.J., Schriefer M.E., et al. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis 2002, 187:1187.
79. Kalish R.A., McHugh G., Granquist J., et al. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis 2001, 33:780.
80. Steere A.C., Sikand V.K., Schoen R.T., et al. Asymptomatic infection with Borrelia burgdorferi. Clin Infect Disease 2003, 37:528.
81. Wormser G.P., Dattwyler R.J., Shapiro E.D., et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Disease Society of America. Clin Infect Dis 2006, 43:1089-1134.
82. Dattwyler R.J., Volkman D.J., Conaty S.M., et al. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet 1990, 336:1404-1406.
83. Massarotti E.M., Luger S.W., Rahn D.W., et al. Treatment of early Lyme disease. Am J Med 1992, 92:396.
84. Nadelman R.B., Luger S.W., Frank E., et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992, 117:273.
85. Logigian E.L., Kaplan R.F., Steere A.C. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. J Infect Dis 1999, 180:377.
86. Dattwyler R.J., Halperin J.J., Volkman D.J., et al. Treatment of late Lyme borreliosis-randomized comparison of ceftriaxone and penicillin. Lancet 1988, 1:1191.
87. Steere A.C., Levin R.E., Molloy P.J., et al. Treatment of Lyme arthritis. Arthritis Rheum 1994, 37:878.
88. Shapiro E.D., Gerber M.A., Holabird N.B., et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer tick bites. N Engl J Med 1992, 327:1769.
89. Piesman J. Dynamics of Borrelia burgdorferi transmission by nymphal Ixodes dammini ticks. J Infect Dis 1993, 167:1082-1085.
90. Nadelman R.B., Nowakowski J., Fish D., et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001, 345:79.
91. Klempner M.S., Hu L.T., Evans J., et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001, 345:84.
92. Krupp L.B., Hyman L.G., Grimson R., et al. Study and treatment of post Lyme disease: a randomized double masked clinical trial. Neurology 2003, 60:1923.
93. Fallon B.A., Keilp J.G., Corbera K.M., et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy in Lyme encephalopathy. Neurology 2008, 70:992.
94. Steere A.C., Malawista S.E. Cases of Lyme disease in the United States: locations correlated with distribution of Ixodes dammini. Ann Intern Med 1979, 91:730.
95. Dennis D.T., Hayes E.B. Epidemiology of Lyme borreliosis. Lyme borreliosis: biology, epidemiology and control 2002, 251. CABI, Oxford, United Kingdom. O. Kahl, J.S. Gray, R.S. Lane (Eds.).
96. Jones K.L., Glickstein L.J., Damle N., et al. Borrelia burgdorferi genetic markers and disseminated disease in patients with early Lyme disease. J Clin Microbiol 2006, 44:4407.
97. Jones K.L., McHugh G.A., Glickstein L.J., et al. Analysis of Borrelia burgdorferi genotypes in patients with Lyme arthritis: high frequency of ribosomal RNA intergenic spacer type 1 strains in antibiotic-refractory arthritis. Arthritis Rheum 2009, 60:2174-2182.
98. Derdakova M., Dudioak V., Brei B., et al. Interaction and transmission of two Borrelia burgdorferi sensu stricto strains in a tick-rodent maintenance system. Appl Environ Microbiol 2004, 70:6783.
99. Hoen A.G., Margos G., Bent S.J., et al. Phylogeography of Borrelia burgdorferi in the eastern United States reflects multiple independent Lyme disease emergence events. Proc Natl Acad Sci U S A 2009, 106:15013.
100. Margos G., Gatewood A.G., Aanensen D.M., et al. MLST of housekeeping genes captures geographic population structure and suggests a European origin of Borrelia burgdorferi. Proc Natl Acad Sci U S A 2008, 105:8730.
101. Spielman A. The emergence of Lyme disease and human babesiosis in a changing environment. Ann N Y Acad Sci 1994, 740:146.
102. Steere A.C., Sikand V.K., Meurice F., et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface protein lipoprotein A with adjuvant. N Engl J Med 1998, 339:209-215.
103. Brown R.N., Lane R.S. Lyme disease in California: a novel enzootic transmission cycle of Borrelia burgdorferi. Science 1992, 256:1439.
104. Steere A.C. Lyme disease: a growing threat to urban populations. Proc Natl Acad Sci U S A 1994, 91:2378.
105. Hayes E.B., Piesman J. How can we prevent Lyme disease?. N Engl J Med 2003, 348:2424.
106. Johnson R.C., Kodner C., Russell M. Passive immunization of hamsters against experimental infection with Borrelia burgdorferi. Infect Immun 1986, 53:713.
107. Johnson R.C., Kodner C., Russell M. Active immunization of hamsters against experimental infection with Borrelia burgdorferi. Infect Immun 1986, 54:887.
108. Chu H.J., Chavez L.G.J., Blumer B.M., et al. Immunogenicity and efficacy study of a commercial Borrelia burgdorferi bacterin. J Am Vet Med Assoc 1992, 201:403.
109. Levy S.A., Lissman B.A., Ficke C.M. Performance of a Borrelia burgdorferi bacterin in borreliosis-endemic areas. J Am Vet Med Assoc 1993, 202:1834.
110. Fikrig E., Barthold S.W., Kantor F.S., et al. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science 1990, 250:553-556.
111. Schaible U.E., Kramer M.D., Eichmann K., et al. Monoclonal antibodies specific for the outer surface protein A (OspA) of Borrelia burgdorferi prevent Lyme borreliosis in severe combined immunodeficiency (scid) mice. Proc Natl Acad Sci U S A 1990, 87:3768.
112. Sears J.E., Fikrig E., Nakagawa T.Y., et al. Molecular mapping of Osp-A mediated immunity against Borrelia burgdorferi, the agent of Lyme disease. J Immunol 1991, 147:1995.
113. Fikrig E., Telford S.R., Barthold S.W., et al. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proc Natl Acad Sci U S A 1992, 89:5418.
114. Erdile L.F., Brandt M.A., Warakomski D.J., et al. Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA. Infect Immun 1993, 61:81.
115. Roehrig J.T., Piesman J., Hunt A.R., et al. The hamster immune response to tick-transmitted Borrelia burgdorferi differs from the response to needle-inoculated, cultured organisms. J Immunol 1992, 149:3648.
116. Golde W.T., Piesman J., Dolan M.C., et al. Reactivity with a specific epitope of outer surface protein A predicts for protection from infection with the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun 1997, 65:882-889.
117. Philipp M.T., Lobet Y., Bohm R.P., et al. The outer surface protein A (OspA) vaccine against Lyme disease: efficacy in the rhesus monkey. Vaccine 1997, 15:1872.
118. Fikrig E., Barthold S.W., Persing D.H., et al. Borrelia burgdorferi strain 25015: characterization of outer surface protein A and vaccination against infection. J Immunol 1992, 148:2256.
119. Fikrig E., Telford S.R., Wallich R., et al. Vaccination against Lyme disease caused by diverse Borrelia burgdorferi. J Exp Med 1995, 181:215.
120. Dykhuizen D.E., Polin D.S., Dunn J.J., et al. Borrelia burgdorferi is clonal: implications for taxonomy and vaccine development. Proc Natl Acad Sci U S A 1993, 90:10163.
121. Stover C.K., Bansal G.P., Hanson M.S., et al. Protective immunity elicited by recombinant bacille Calmette-Guérin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med 1993, 178:197.
122. Fikrig E., Barthold S.W., Marcantonio N., et al. Roles of OspA, OspB, and flagellin in protective immunity to Lyme borreliosis in laboratory mice. Infect Immun 1992, 60:657.
123. Preac-Mursic V., Wilske B., Patsouris E., et al. Active immunization with pC protein of Borrelia burgdorferi protects gerbils against B. burgdorferi infection. Infection 1992, 20:342.
124. Nguyen T.P., Lam T.T., Barthold S.W., et al. Partial destruction of Borrelia burgdorferi within ticks that engorged on OspE- or OspF-immunized mice. Infect Immun 1994, 62:2079.
125. Hanson M.S., Cassatt D.R., Guo B.P., et al. Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infect Immun 1998, 66:2143.
126. Keller D., Koster F.T., Marks D.H., et al. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA 1994, 271:1764.
127. Van Hoecke C., Comberbach M., De Grave D., et al. Evaluation of the safety, reactogenicity, and immunogenicity of three recombinant outer surface protein (OspA) Lyme vaccines in healthy adults. Vaccine 1996, 14:1620.
128. Wormser G.P. A vaccine against Lyme disease?. Ann Intern Med 1995, 123:627.
129. Meurice F., Parenti D., Fu D., et al. Specific issues in the design and implementation of an efficacy trial for a Lyme disease vaccine. Clin Infect Dis 1997, 25(suppl):S71.
130. American Society of Health-System Pharmacists I: Lyme disease vaccine. AHFS Drug Information 1999 1999, vol. 80:12. American Society of Health-System Pharmacists, Bethesda, MD.
131. Thanassi W.T., Schoen R.T. The Lyme disease vaccine: conception, development, and implementation. Ann Intern Med 2000, 132:661.
132. Rahn D.W. Lyme vaccine: issues and controversies. Infect Dis Clin North Am 2001, 15:171.
133. Poland G.A. Prevention of Lyme disease: a review of the evidence. Mayo Clin Proc 2001, 76:713.
134. Kamradt T. Lyme disease and current aspects of immunization. Arthritis Res 2002, 4:20.
135. Hanson M.S., Edelman R. Progress and controversy surrounding vaccines against Lyme disease. Expert Rev Vaccines 2003, 2:683.
136. Parenti D., Schoen R., Sikand V., et al. Evaluation of reactogenicity and immunogenicity of LYMErix, recombinant L-OspA vaccine against Lyme disease, administered on two different schedules [abstract]. Abstracts of the annual meeting of the Infectious Diseases Society of America 1998, 705. Denver, CO.
137. Van Hoecke C., Lebacq E., Beran J., et al. Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine. Clin Infect Dis 1999, 28:1260.
138. Parenti D., Gillet M., Sennewald E., et al. Correlate of protection for Lyme disease (LD) using LYMErix recombinant adjuvanted Borrelia burgdorferi outer surface lipoprotein A (L-OspA) vaccine [abstract]. Abstracts of the annual meeting of the Infectious Diseases Society of America 1998, 704. Denver, CO.
139. Alexopoulou L., Thomas V., Schmare M., et al. Hyporesponsiveness to vaccination with Borrelia burgdorferi in humans and in TLR1- and TLR2-deficient mice. Nat Med 2002, 8:878.
140. Sikand V.K., Halsey N., Krause P.J., et al. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in healthy children and adolescents: a randomized controlled trial. Pediatrics 2001, 108:123.
141. Sigal L.H., Zahradnik J.M., Lavin P., et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium [see comments]. N Engl J Med 1998, 339:216-222. (See erratum in N Engl J Med 339:571, 1998.).
142. Steere A.C., Dhar A., Hernandez J., et al. Systemic symptoms without erythema migrans as the presenting picture of early Lyme disease. Am J Med 2003, 114:58.
143. Steere A.C., Angelis S.M. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 2006, 54:3079.
144. Steere A.C., Glickstein L. Elucidation of Lyme arthritis. Nat Rev Immunol 2004, 4:143.
145. Steere A.C., Klitz W., Drouin E.E., et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med 2006, 203:961.
146. Chen J., Field J.A., Glickstein L., et al. Association of antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant epitopes of outer-surface protein A (OspA) of Borrelia burgdorferi. Arthritis Rheum 1999, 42:1813.
147. Gross D.M., Forsthuber T., Tary-Lehman M., et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998, 281:703.
148. Meyer A.L., Trollmo C., Crawford F., et al. Direct enumeration of Borrelia-reactive CD4. T cells ex vivo by using MHC class II tetramers. Proc Natl Acad Sci U S A 2000, 97:11433.
149. 161-175 epitope associated with treatment-resistant Lyme arthritis: differences among the three pathogenic species of Borrelia burgdorferi sensu lato. J Autoimmun 2004, 23:281.
150. Trollmo C., Meyer A.L., Steere A.C., et al. Molecular mimicry in Lyme arthritis demonstrated at the single cell level: LFA-1α is a partial agonist for outer-surface protein A-reactive T cells. J Immunol 2001, 166:5286.
151. Steere A.C., Falk B., Drouin E.E., et al. Binding of outer surface protein A and human lymphocyte function-associated 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum 2003, 48:534.
152. Schoen R.T., Meurice F., Brunet C.M., et al. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. J Infect Dis 1995, 172:1324.
153. Rose C.D., Fawcett P.T., Gibney K.M. Arthritis following recombinant outer surface protein A vaccination for Lyme disease. J Rheumatol 2001, 28:2555.
154. Lathrop S.L., Ball R., Haber P., et al. Adverse event reports following vaccination for Lyme disease: December 1998-July 2000. Vaccine 2002, 20:1603.
155. Ball R., Shadomy S.V., Meyer A., et al. HLA type and immune response to Borrelia burgdorferi outer surface protein A in people in whom arthritis developed after Lyme disease vaccination. Arthritis Rheum 2009, 60:1179.
156. Steere A.C., Drouin E.E., Glickstein L.J. Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis. Clin Infect Dis 2011, 52:S259-S265.
157. Iliopoulou B.P., Guerau-De-Arellano M., Huber B.T. HLA-DR alleles determine responsiveness to Borrelia burgdorferi antigens in a mouse model of self-perpetuating arthritis. Arthritis Rheum 2009, 60:3831-3840.
158. Maes E., Lecomte P., Ray N. A cost-of-illness study of Lyme disease in the United States. Clin Ther 1998, 20:993-1008.
159. Meltzer M.I., Dennis D.T., Orloski K.A. The cost effectiveness of vaccinating against Lyme disease. Emerg Infect Dis 1999, 5:1.
160. Shadick N.A., Liang M.H., Phillips C., et al. The cost-effectiveness of vaccination against Lyme disease. Arch Intern Med 2001, 161:554.
161. Recommendations for the use of the Lyme disease vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999, 48(RR-7):1-17. 21-25.
162. Abbott A. Uphill struggle. Nature 2006, 439:524.
163. Nigrovic L.E., Thompson K.M. The Lyme vaccine, a cautionary tale. Epidemiol Infect 2007, 135:1.
164. Poland G.A. Vaccines against Lyme disease: what happened and what lessons can be learned. Clin Infect Dis 2011, 52:S253.
165. Plotkin S.A. Correcting a public health fiasco: the need for a new vaccine against Lyme disease. Clin Infect Dis 2011, 52:S271-S275.
166. Livey I., O'Rourke M., Traweger A., et al. A new approach to a Lyme disease vaccine. Clin Infect Dis 2011, 52:S266-S270.
167. Willett T.A., Meyer A.L., Brown E.L., et al. An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope. Proc Natl Acad Sci U S A 2004, 101:1303.
168. Nassal M., Skamel C., Kratz P., et al. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula. Eur J Immunol 2005, 35:655.
169. Koide S., Yang X., Huang X., et al. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA. J Mol Biol 2005, 350:290.
170. Wilske B., Busch U., Fingerle V., et al. Immunological and molecular variability of OspA and OspC: implications for Borrelia vaccine development. Infection 1996, 24:208.
171. Ivanova L., Christova I., Neves V., et al. Comprehensive seroprofiling of sixteen B. burgdorferi OspC: implications for Lyme disease diagnostic design. Clin Immunol 2009, 132:393.
172. Earnhart C.G., Buckles E.L., Marconi R.T. Development of an OspC-based tetravalent, recombinant, chimeric vaccinogen that elicits bactericidal antibody against diverse Lyme disease spirochete strains. Vaccine 2007, 25:466.
173. Tsao J.I., Wootton J.T., Bunikis J., et al. An ecological approach to preventing human infection: vaccinating wild mouse reservoirs intervenes in the Lyme disease cycle. Proc Natl Acad Sci U S A 2004, 52:18159.
174. LaGiudice K., Ostfeld R.S., Schmidt K.A., et al. The ecology of infectious disease: effects of host diversity and community composition on Lyme disease risk. Proc Natl Acad Sci U S A 2003, 100:567.
175. Scheckelhoff M.R., Telford S.R., Hu L.T. Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs. Vaccine 2006, 24:1949-1957.
176. Gomes-Solecki M.JC., Brisson D.R., Dattwyler R.J. Oral vaccine that breaks the transmission cycle of the Lyme disease spirochete can be delivered via bait. Vaccine 2006, 24:4440.
177. Brooks C.S., Vuppala S.R., Jett A.M., et al. Identification of Borrelia burgdorferi outer-surface proteins. Infect Immun 2006, 74:296.
178. Stubs G., Fingerle V., Wilske B., et al. Acylated cholesteryl galactosides are specific antigens of Borrelia causing Lyme disease and frequently induce antibodies in late stages of disease. J Biol Chem 2009, 284:13326-13334.
179. Stubs G., Rupp B., Schumann R.R., et al. Chemoenzymatic synthesis of a glycolipid library and elucidation of the antigenic epitope for construction of a vaccine against Lyme disease. Chemistry 2010, 16:3536.
180. Hovius J.W., van Dam A.P., Fikrig E., et al. Tick-host-pathogen interactions in Lyme borreliosis. Trends Parasitol 2007, 23:434.
181. Schuijt T.J., Hovius J.W., van der Poll T., et al. Lyme borreliosis vaccination: the facts, the challenge, the future. Trends Parisitol 2011, 27:40.
182. Dai J., Wang P., Adusumilli S., et al. Antibodies against a tick protein, Salp15, protect mice from the Lyme disease agent. Cell Host Microbe 2009, 6:482-492.
183. Narasimhan S., DePonte K., Marcantonio N., et al. Immunity against Ixodes scapularis salivary proteins expressed during the first 24 hours of attachment thwarts tick feeding and impairs Borrelia transmission. PloS One 2007, 2:e451.
184. Shen A.K., Mead P.S., Beard C.B. The Lyme disease vaccine: a public health perspective. Clin Infect Dis 2011, 52:S247-S252.